ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO211

Association of Thyroid Function with Prevalence and Development of CKD

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Toda, Akiko, Toranomon Hospital, Tokyo, Japan
  • Tsuji, Hiroshi, Toranomon Hospital, Tokyo, Japan
  • Hara, Shigeko, Toranomon Hospital, Tokyo, Japan

Previous cross-sectional studies indicated an association between hypothyroidism and kidney dysfunction, but few studies have investigated aboutthyroid dysfunction and chronic kidney disease (CKD), especially whether thyroid dysfunction is a risk factor for CKD development.


Using the data of annual health check-ups, we evaluated a relationship of thyroid dysfunction with CKD prevalence and development by a multivariate logistic regression analysis. In cross-sectional and longitudinal studies, 16,390 subjects and 7,609 subjects were analyzed, respectively. We categorized the subjects into four groups based on their serum thyroid-stimulating hormone (TSH) concentrations;below-normal (TSH <0.54 mU/L), lower-normal (0.54–2.40 mU/L), higher-normal (2.40–4.26 mU/L) and above-normal (>4.26 mU/L). As covariate factors, age, gender, obesity, hypertension, dyslipidemia, hyperuricemia, diabetes mellitus, proteinuria, and hematuria were adjusted in cross-sectional study. In longitudinal study, the baseline eGFR was added to the covariate factors of the cross-sectional study.


The cross-sectional study revealed a positive correlation between the TSH concentration and CKD prevalence. Compared with the lower-normal TSH group, the odds ratios (ORs) and 95% confidence intervals (CI) of CKD prevalence were 0.609 (0.452–0.821, p= 0.001) for the below-normal group, 1.492 (1.332–1.672, p<0.001) for the higher-normal group, and 1.900 (1.568–2.302, p<0.001) for the above-normal group. The longitudinal study revealed that the risk of CKD development within three years was significantly higher in the above-normal TSH group compared with the lower-normal TSH group: OR 1.578, 95% CI 1.016–2.451, p= 0.042. However, no significances of CKD development risk in the below-normal TSH group and the higher-normal TSH group were observed.


Our data indicated that a higher TSH concentration has a positive correlation with CKD prevalence, and that a high TSH concentration is a risk factors for CKD development. These results suggest thatthyroid function screening might be informative in patients whose eGFR declines without a clear cause, and thyroid hormone replacement therapy for hypothyroidism patients could have an effect on preventing CKD development.